Physician profile
Marcelo V Bendix
NPI 1053365551
$32,551.16
in general payments reported to CMS, 2019-2025
33 companies · $2,745 in 2025
The $2,745 reported for 2025 was more than what 82% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,857 · 2020: $17K · 2021: $2,766 · 2022: $2,430 · 2023: $2,311 · 2024: $2,011 · 2025: $2,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,066.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $21,646.39 | 2019-2025 | Omnipod |
| Novo Nordisk INC | $3,667.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $1,260.25 | 2020-2024 | Afrezza |
| Sanofi-Aventis U.S. LLC | $1,121.03 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $742.24 | 2019-2022 | |
| Dexcom, INC. | $485.17 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Lilly USA, LLC | $481.84 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Zealand Pharma US, INC. | $415.02 | 2020-2022 | |
| Medtronic, INC. | $260.47 | 2021-2023 | Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System |
| Corcept Therapeutics | $241.74 | 2021-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $232.40 | 2021-2023 | |
| Tandem Diabetes Care, INC. | $228.41 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lifescan, INC. | $215.21 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.24 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amarin Pharma, INC. | $198.26 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $144.14 | 2021-2025 | |
| Cequr Corporation | $126.43 | 2023-2024 | Cequr Simplicity |
| Abbott Laboratories | $123.09 | 2021-2024 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $122.24 | 2022-2025 | Unithroid |
| Xeris Pharmaceuticals, INC. | $114.34 | 2021-2025 | Gvoke Hypopen |
| Radius Health, INC. | $94.74 | 2020 | |
| Amgen INC. | $69.04 | 2022-2025 | Repatha, Repatha, Evenity |
| Ibsa Pharma INC. | $54.25 | 2022-2023 | Tirosint, Licart |
| Kyowa Kirin, INC. | $49.68 | 2023-2024 | Crysvita |
| Halozyme INC | $47.24 | 2023 | |
| Embecta Corp. | $37.81 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Recordati_rare_diseases_inc. | $34.01 | 2025 | Isturisa |
| Novartis Pharmaceuticals Corporation | $32.00 | 2024 | |
| Becton, Dickinson and Company | $22.75 | 2022 | |
| Madrigal Pharmaceuticals | $22.11 | 2024 | Resmetirom |
| Ascendis Pharma Endocrinology INC | $21.35 | 2025 | Yorvipath |
| Exact Sciences Corporation | $21.25 | 2023 | Cologuard Collection Kit |
| Acerus Pharmaceuticals Corporation | $16.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcelo Bendix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.